Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 12/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1725707 | 1.00 | BDKRB1 (0.42) | BDKRB1LMNATAS1R3TAS1R1TAS1R2 | |
| SCHEMBL13936478 | 1.00 | BDKRB1 (0.42) | BDKRB1LMNATAS1R3TAS1R1TAS1R2 | |
| SCHEMBL13131623 | 0.85 | TRPV1 (0.37) | — | |
| SCHEMBL13936477 | 0.85 | ALDH1A1 (0.44) | BDKRB1LMNATAS1R3TAS1R1TAS1R2 | |
| SCHEMBL1725050 | 0.85 | ALDH1A1 (0.44) | BDKRB1LMNATAS1R3TAS1R1TAS1R2 | |
| SCHEMBL1725049 | 0.85 | ALDH1A1 (0.44) | BDKRB1LMNATAS1R3TAS1R1TAS1R2 | |
| SCHEMBL3537141 | 0.84 | CFD (0.49) | BDKRB1LMNATAS1R3TAS1R1TAS1R2 | |
| SCHEMBL3537138 | 0.84 | CFD (0.49) | BDKRB1LMNATAS1R3TAS1R1TAS1R2 | |
| SCHEMBL3532767 | 0.84 | ALDH1A1 (0.43) | BDKRB1LMNATAS1R3TAS1R1TAS1R2 | |
| SCHEMBL3532766 | 0.84 | ALDH1A1 (0.43) | BDKRB1LMNATAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2403854-B1 | SULFONYLATED TETRAHYDROAZOLOPYRAZINES AND THEIR USE AS MEDICINAL PRODUCTS | GRUENENTHAL GMBH (DE) | 2013-09-11 | — | — | EP | disclosed |
| US-8158628-B2 | Sulfonylated 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine compounds and their use as pharmaceuticals | GRUENENTHAL GMBH (DE) | 2012-04-17 | — | — | US | disclosed |
| EP-2403854-A1 | SULFONYLATED TETRAHYDROAZOLOPYRAZINES AND THEIR USE AS MEDICINAL PRODUCTS | Grünenthal GmbH (DE) | 2012-01-11 | — | — | EP | disclosed |
| US-20100234387-A1 | Sulfonylated Tetrahydroazolopyrazines and their Use as Pharmaceuticals | GRUENETHAL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| WO-2010099938-A1 | SULFONYLATED TETRAHYDROAZOLOPYRAZINES AND THEIR USE AS MEDICINAL PRODUCTS | Grünenthal GmbH (DE) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234387-A1 | Sulfonylated Tetrahydroazolopyrazines and their Use as Pharmaceuticals | BDKRB1, BDKRB2, KCNB1 | BDKRB1 1/4885LMNA 2053/4885TAS1R3 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.